F Tomaka

LONG-TERM FOLLOW-UP OF PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN: INTERIM ANALYSIS OF THE EXTEND STUDY

Stefan Zeuzem, Sulkowski, Fabien Zoulim et al. · 2010 · 53 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +14

Effects of ritonavir‐boosted darunavir <i>vs</i>. ritonavir‐boosted atazanavir on lipid and glucose parameters in HIV‐negative, healthy volunteers

F Tomaka, Éric Lefebvre, V. Sekar et al. · HIV Medicine · 2009 · 44 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Etravirine in treatment‐experienced, <scp>HIV</scp>‐1‐infected children and adolescents: 48‐week safety, efficacy and resistance analysis of the phase <scp>II PIANO</scp> study

Gareth Tudor‐Williams, Pedro Cahn, Kulkanya Chokephaibulkit et al. · HIV Medicine · 2014 · 24 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Subgroup analysis of virological response rates with once‐ and twice‐daily darunavir/ritonavir in treatment‐experienced patients without darunavir resistance‐associated mutations in the <scp>ODIN</scp> trial

Michael Sension, Pedro Cahn, Peré Domingo et al. · HIV Medicine · 2013 · 14 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

55 FUTILITY RULES IN TELAPREVIR COMBINATION TREATMENT

I.M. Jacobson, Doug J. Bartels, Linda Gritz et al. · Journal of Hepatology · 2012 · 12 citations

Pharmacy, Pharmacotherapy, Immunotherapy +1